Analysts Offer Insights on Healthcare Companies: Perrigo Company plc (PRGO), Aptose Biosciences (APTO) and Heron Therapeutics (HRTX)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Perrigo Company plc (PRGO), Aptose Biosciences (APTO) and Heron Therapeutics (HRTX) with bullish sentiments.

Perrigo Company plc (PRGO)

In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Perrigo Company plc, with a price target of $107. The company’s shares closed yesterday at $48.81.

Chen noted:

“We rate PRGO OW with a 12-month price target of $107. We think the company’s growth prospects and earnings potential are underappreciated. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $107.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 13.1% and a 42.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Perrigo Company plc with a $65.20 average price target.

See today’s analyst top recommended stocks >>

Aptose Biosciences (APTO)

In a report released yesterday, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aptose Biosciences, with a price target of $8.50. The company’s shares closed yesterday at $1.89, close to its 52-week low of $1.78.

Pantginis said:

“Valuation and impediments to achieving price target. We reiterate our Buy and $8.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from both the CG-806 opportunity in AML and APTO-253 opportunity in AML and MDS. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -16.6% and a 27.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Dova Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aptose Biosciences with a $7.25 average price target.

Heron Therapeutics (HRTX)

In a report issued on February 22, Boris Peaker from Cowen & Co. maintained a Buy rating on Heron Therapeutics, with a price target of $54. The company’s shares closed yesterday at $27.67.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.4% and a 44.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Heron Therapeutics with a $54.60 average price target, implying a 97.3% upside from current levels. In a report issued on February 22, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $50 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts